In the preclinical mouse model of hepatic, prostate and breast cancer, inhibition of the dipeptidyl-peptidase 4 (DPP4) with the FDA approved drug sitagliptin enhances host eosinophil-mediated antitumoral activity and contribute to ICB efficacy [161]. The gene discussed is DPP4; the disease is breast cancer.